亿帆医药(002019.SZ)：子公司签署独家商业合作协议及相关

Core Viewpoint - Yifan Pharmaceutical (002019.SZ) has signed exclusive agreements with Shangde Yaoyuan and Tianjin Shangde, granting Yifan the exclusive rights to develop, produce, and commercialize a specific drug compound within designated areas and fields [1] Group 1 - Yifan Pharmaceutical's wholly-owned subsidiary, Yifan Pharmaceutical Co., has entered into exclusive agreements with Shangde Yaoyuan and Tianjin Shangde [1] - The agreements allow Yifan to use the licensed intellectual property to develop, produce, and commercialize the drug compound, which is a derivative of dimethylaminomethyl-1,2,3,4-tetrahydroisoquinoline fumarate monohydrate [1] - Yifan is required to pay an upfront fee of 100 million yuan, with options for a cornerstone investment of 100 million yuan or milestone payments of 50 million yuan, along with a tiered revenue-sharing model based on net sales [1]